Relapsed/Refractory Diffuse Large B-cell Lymphoma
15 clinical trials · Condition
◉ Watch Relapsed/Refractory Diffuse Large B-cell Lymphoma
| Record | Firm | Date |
|---|---|---|
| GPL in Patients with Relapsed/refractory Diffuse Large B Cell Lymphoma (NCT05335018) | Seoul National University Hospital | 2022-05-30 |
| A Study of ATG-010 in Combination With ATG-008 in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (NCT05354362) | Antengene Corporation | 2022-03-02 |
| Zanubrutinib, in Combination With Lenalidomide, With or Without Rituximab in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (NCT04436107) | BeiGene | 2020-09-11 |
| A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (NCT04442022) | Karyopharm Therapeutics Inc | 2020-09-03 |
| A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies (NCT03886831) | Prelude Therapeutics | 2019-02-11 |
| Axicabtagene Ciloleucel Expanded Access Study (NCT03153462) | Kite, A Gilead Company |
Track Relapsed/Refractory Diffuse Large B-cell Lymphoma automatically
Every clearance here is in the API, with alerts when new ones post.